Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 4:14:1214041.
doi: 10.3389/fneur.2023.1214041. eCollection 2023.

Diagnosis and therapy of myasthenia gravis-the patients' perspective: a cross-sectional study

Tomasz Sobierajski  1 , Anetta Lasek-Bal  2   3 , Marek Krzystanek  4 , Nils E Gilhus  5   6
Affiliations

Diagnosis and therapy of myasthenia gravis-the patients' perspective: a cross-sectional study

Tomasz Sobierajski et al. Front Neurol. .

Abstract

The survey aimed to explore patients' perspectives with myasthenia gravis (MG) toward the diagnosis made and the therapy used to treat MG. The survey was conducted with a quantitative method, using the CAWI technique. A total of 321 people participated in the survey. More than half of the respondents (56.4%) had suffered from MG for less than 10 years. In three out of 10 cases (30.9%), the diagnosis of MG lasted 3 years or longer. The diagnostic delay was significantly longer in female respondents than in the males (p = 0.029). Cholinergic drugs were used in 92.9% of cases initially, and as maintenance therapy in 84.3% of cases. Corticosteroids were used in initiating therapy (45.8%) and as maintenance therapy (46.4%). One in four respondents (25.5%) reported experiencing very strong and strong side effects after using steroids. The side effects from steroid therapy very strong or strong affected overall physical health in 55.9% of respondents, very strong or strong affected self-acceptance in 52%, to a very large or large extent on mental health in 47.1%, and to a very strong or strong extent influenced the performance of daily activities in 28.2%. More than half of the respondents (57.0%) had had a thymectomy. Seven out of 10 respondents (72.0%) declared that the therapy they were on at the time of the survey allowed them (to varying degrees) to control their course of MG. Low therapy acceptance and less well controlled MG was associated with a preference for non-tablet therapies (p = 0.045). Regular follow-up and cooperation with the specialist health care system should improve MG symptoms, activities of daily living, and quality of life.

Keywords: Poland; corticosteroids; mental health; physical health; thymoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Distribution of initiating therapy and maintenance therapy in all included patients (N = 321). CH, cholinergic; STR, steroid therapy; IP, immunosuppressants; IM, immunoglobulins; PL, plasmapheresis; CT, clinical trial; PS, parasympathomimetics; and R, remission.
Figure 2
Figure 2
Does the therapy you are currently using control allow to control MG? (N = 321).
Figure 3
Figure 3
Does the therapy you are currently using meet your expectations? (N = 321).
Figure 4
Figure 4
Preferred application form of the drugs (N = 321).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Somnier FE, Engel PJ. The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999. Neurology. (2002) 59:92–8. doi: 10.1212/wnl.59.1.92, PMID: - DOI - PubMed
    1. Fang W, Li Y, Mo R, Wang J, Qiu L, Ou C, et al. . Hospital and healthcare insurance system record-based epidemiological study of myasthenia gravis in southern and northern China. Neurol Sci. (2020) 41:1211–23. doi: 10.1007/s10072-019-04146-1, PMID: - DOI - PubMed
    1. Bettini M, Chaves M, Cristiano E, Pagotto V, Perez L, Giunta D, et al. . Incidence of autoimmune myasthenia gravis in a health maintenance Organization in Buenos Aires. Argentina Neuroepidemiol. (2017) 48:119–23. doi: 10.1159/000477733, PMID: - DOI - PubMed
    1. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. (2010) 10:46. doi: 10.1186/1471-2377-10-46, PMID: - DOI - PMC - PubMed
    1. Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. (2019) 5:30. doi: 10.1038/s41572-019-0079-y - DOI - PubMed

LinkOut - more resources